Mitochondrial dysfunction activates lysosomal-dependent mitophagy selectively in cancer cells.

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Mitochondria-targeted molecules are promising for cancer therapy.
• Mitochondria-targeted redox agents (MTAs) cause mitochondrial damage and autophagy.
• Mechanisms of MTA-induced mitophagy remain largely unknown.

Purpose of the Study:

• Investigate the mechanisms by which MTAs induce mitophagy.
• Determine if MTA-induced mitophagy is selective for cancer cells.
• Explore the therapeutic potential of MTAs.

Main Methods:

• Utilized breast cancer cell lines (MDA-MB-231) and non-cancerous cells (MCF-12A).
• Administered targeted molecules and performed kinetic analyses.
• Generated cell lines expressing mitochondrial mKeima (pH sensor) for mitophagy assessment.
• Confirmed mitophagy via PINK1 accumulation in autophagosomes and MFN2-LC3-II complex formation.

Main Results:

• Mitochondrial dysfunction and autophagy were selective for MDA-MB-231 cancer cells.
• Mitochondrial dysfunction preceded autophagy activation.
• MTAs induced lysosome-dependent mitochondrial degradation in cancer cells.
• Evidence confirmed mitophagy activation.

Conclusions:

• Mitochondrial redox agents selectively induce mitophagy in a breast cancer cell line.
• These agents can be tools for studying mitochondrial biomechanics.
• MTAs represent potential therapeutic strategies targeting mitochondrial metabolism in cancer.